Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 4.58 (-0.09), PCYC: 132.65 (-2.34), TGTX: 18.25 (+0.74), ONTX: 3.86 (-0.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), AZN: 71.80 (-1.80), ABBV: 65.27 (-1.76), INFI: 17.78 (-0.21), CELGZ: 3.51 (-0.03), NVS: 93.52 (-0.82)
T-Cell Lymphomas - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wvfhz/tcell_lymphomas) has announced the addition of the "T-Cell Lymphomas - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Lymphomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - arGEN-X - Bristol-Myers Squibb - Celgene - Cell Medica - Infinity Pharmaceuticals - Karyopharm Therapeutics - Kyowa Hakko Kirin - Nippon Kayaku - Novartis - Ono Pharmaceutical - Onyx Pharmaceuticals - Pharma Mar - Pharmacyclics - Seattle Genetics - Sigma-Tau For more information visit http://www.researchandmarkets.com/research/2w..._lymphomas
INFI: 17.78 (-0.21), BMY: 58.75 (-0.93), NVS: 93.52 (-0.82), KPTI: 34.85 (+1.35), CELGZ: 3.51 (-0.03)
Infinity Reports New Results from Phase 1 Study of Investigational Oncology Compound Duvelisib at the American Society of Hematology Annual Meeting
Business Wire - Tue Dec 09, 10:30AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported updated data from a Phase 1 monotherapy study of duvelisib (IPI-145), an inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which showed activity among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), a fatal type of blood cancer. In the study, duvelisib demonstrated an overall response rate of 72 percent, including a 33 percent complete response rate, among 18 patients with iNHL who received the dose administered in ongoing registration-focused studies. In a separate presentation, updated Phase 1 data were also reported showing the activity of duvelisib in patients with relapsed/refractory T-cell lymphoma. These data were presented today at the 56th Annual Meeting of the American Society of Hematology (ASH).
INFI: 17.78 (-0.21)
Infinity Pharmaceuticals Has Returned 40.5% Since SmarTrend Recommendation (INFI)
Comtex SmarTrend(R) - Tue Dec 09, 9:09AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 4 months, Infinity Pharmaceuticals has returned 40.47% as of today's recent price of $15.80.
INFI: 17.78 (-0.21)
Infinity Reports New Translational Research and Updated Phase 1 Data of Investigational Oncology Compound Duvelisib at American Society of Hematology Annual Meeting
Business Wire - Mon Dec 08, 9:45AM CST
--- Updated Phase 1 Data Highlight Duvelisib Activity as a Monotherapy in Relapsed/Refractory Chronic Lymphocytic Leukemia -
INFI: 17.78 (-0.21)
Upgrade Alert for Infinity Pharmaceuticals (INFI)
Comtex SmarTrend(R) - Thu Dec 04, 6:55AM CST
Infinity Pharmaceuticals (NASDAQ:INFI) was upgraded from Neutral to Outperform at Credit Suisse today. The stock closed yesterday at $15.38 on volume of 764,000 shares, above average daily volume of 610,000. Infinity Pharmaceuticals, Inc. researches and develops cancer drugs. The Company uses small molecule drug technologies in the development of its products.
INFI: 17.78 (-0.21)
Shares of INFI Up 32.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 01, 4:43PM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 4 months, Infinity Pharmaceuticals has returned 32.77% as of today's recent price of $14.93.
INFI: 17.78 (-0.21)
Infinity Pharmaceuticals (INFI) Is Today's Strong On High Volume Stock
at The Street - Wed Nov 26, 9:02AM CST
Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate
INFI: 17.78 (-0.21)
Infinity Pharmaceuticals Shares Up 26.3% Since SmarTrend's Buy Recommendation (INFI)
Comtex SmarTrend(R) - Mon Nov 24, 11:10AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 3 months, Infinity Pharmaceuticals has returned 26.32% as of today's recent price of $14.21.
INFI: 17.78 (-0.21)
Post Earnings Update: Infinity Pharmaceuticals Has Climbed 17.1% Higher in Past 2 Weeks (INFI)
Comtex SmarTrend(R) - Mon Nov 24, 8:55AM CST
Two weeks ago on November 6th, 2014 Infinity Pharmaceuticals (NASDAQ:INFI) reported earnings and analysts, on average, expected earnings of $1.26 on sales of $137.5 million. Infinity Pharmaceuticals actually reported earnings of $2.03 per share on sales of $160.6 million, beating EPS estimates by $0.77 and beating revenue estimates by $23.1 million. Since the company's report, shares of Infinity Pharmaceuticals have risen from $12.14 to $14.21, representing a gain of 17.1% in the past 18 days.
INFI: 17.78 (-0.21)
Infinity to Present at the Deutsche Bank Securities 2014 BioFEST Conference
Business Wire - Mon Nov 24, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the Deutsche Bank Securities 2014 BioFEST Conference on December 1, 2014 at 2:15 p.m. ET in Boston.
DB: 30.78 (-0.56), INFI: 17.78 (-0.21)
Infinity Pharmaceuticals Earnings In Retrospect: Up 16.1% in the Last 11 Days (INFI)
Comtex SmarTrend(R) - Mon Nov 17, 1:03PM CST
When Infinity Pharmaceuticals (NASDAQ:INFI) reported earnings 11 days ago on November 6th, 2014, analysts, on average, expected the company to report earnings of $1.26 on sales of $137.5 million. Infinity Pharmaceuticals actually reported earnings of $2.03 per share on sales of $160.6 million, beating EPS estimates by $0.77 and beating revenue estimates by $23.1 million. Since the company's report, shares of Infinity Pharmaceuticals have risen from $12.14 to $14.10, representing a gain of 16.1% in the past 11 days.
INFI: 17.78 (-0.21)
Infinity Pharmaceuticals Has Returned 26.0% Since SmarTrend Recommendation (INFI)
Comtex SmarTrend(R) - Mon Nov 17, 10:19AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 3 months, Infinity Pharmaceuticals has returned 26.01% as of today's recent price of $14.17.
INFI: 17.78 (-0.21)
Infinity Pharmaceuticals (INFI) Is Strong On High Volume Today
at The Street - Fri Nov 14, 9:08AM CST
Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate
INFI: 17.78 (-0.21)
Infinity Pharmaceuticals (INFI) Upgraded From Sell to Hold
at The Street - Fri Nov 14, 8:39AM CST
Infinity Pharmaceuticals (INFI) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
INFI: 17.78 (-0.21)
Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 5:14PM CST
INFI: 17.78 (-0.21)
Infinity beats 3Q profit forecasts
Automated Insights - Thu Nov 06, 4:54PM CST
CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Thursday reported third-quarter net income of $103.2 million.
INFI: 17.78 (-0.21)
Infinity Pharmaceuticals (INFI) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:25PM CST
INFI: 17.78 (-0.21)
Infinity Pharmaceuticals EPS of $2.03
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:19PM CST
INFI: 17.78 (-0.21)